Carboplatin versus cisplatin

J. B. Vermorken; W. W. Ten Bokkel Huinink; E. A. Eisenhauer; G. Favalli; D. Belpomme; P. F. Conte; S. B. Kaye

Carboplatin versus cisplatin

J. B. Vermorken, W. W. Ten Bokkel Huinink, E. A. Eisenhauer, G. Favalli, D. Belpomme, P. F. Conte, S. B. Kaye

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Since the introduction of the second generation platinum compound carboplatin, debate has taken place about whether this analogue can replace cisplatin in combination chemotherapy regimens for the treatment of ovarian cancer patients. Materials and methods: In the present review the pharmacologic characteristics of carboplatin and cisplatin and the results of comparative studies are described. Results: Many of the trials performed comparing carboplatin with cisplatin, either as single agent first-line therapy or in combination chemotherapy suggest equivalent results. However, most of these trials are characterized by an inadequate patient number to detect small but important differences, inadequate carboplatin doses, ratios

Original language	English
Journal	Annals of Oncology
Volume	4
Issue number	SUPPL. 4
Publication status	Published - 1993

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Carboplatin versus cisplatin'. Together they form a unique fingerprint.

Cite this

@article{ee77a741f4bc4ab389e3ac9af0482a4f,

title = "Carboplatin versus cisplatin",

abstract = "Background: Since the introduction of the second generation platinum compound carboplatin, debate has taken place about whether this analogue can replace cisplatin in combination chemotherapy regimens for the treatment of ovarian cancer patients. Materials and methods: In the present review the pharmacologic characteristics of carboplatin and cisplatin and the results of comparative studies are described. Results: Many of the trials performed comparing carboplatin with cisplatin, either as single agent first-line therapy or in combination chemotherapy suggest equivalent results. However, most of these trials are characterized by an inadequate patient number to detect small but important differences, inadequate carboplatin doses, ratios ",

author = "Vermorken, {J. B.} and {Ten Bokkel Huinink}, {W. W.} and Eisenhauer, {E. A.} and G. Favalli and D. Belpomme and Conte, {P. F.} and Kaye, {S. B.}",

year = "1993",

language = "English",

volume = "4",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "SUPPL. 4",

}

TY - JOUR

T1 - Carboplatin versus cisplatin

AU - Vermorken, J. B.

AU - Ten Bokkel Huinink, W. W.

AU - Eisenhauer, E. A.

AU - Favalli, G.

AU - Belpomme, D.

AU - Conte, P. F.

AU - Kaye, S. B.

PY - 1993

Y1 - 1993

N2 - Background: Since the introduction of the second generation platinum compound carboplatin, debate has taken place about whether this analogue can replace cisplatin in combination chemotherapy regimens for the treatment of ovarian cancer patients. Materials and methods: In the present review the pharmacologic characteristics of carboplatin and cisplatin and the results of comparative studies are described. Results: Many of the trials performed comparing carboplatin with cisplatin, either as single agent first-line therapy or in combination chemotherapy suggest equivalent results. However, most of these trials are characterized by an inadequate patient number to detect small but important differences, inadequate carboplatin doses, ratios

AB - Background: Since the introduction of the second generation platinum compound carboplatin, debate has taken place about whether this analogue can replace cisplatin in combination chemotherapy regimens for the treatment of ovarian cancer patients. Materials and methods: In the present review the pharmacologic characteristics of carboplatin and cisplatin and the results of comparative studies are described. Results: Many of the trials performed comparing carboplatin with cisplatin, either as single agent first-line therapy or in combination chemotherapy suggest equivalent results. However, most of these trials are characterized by an inadequate patient number to detect small but important differences, inadequate carboplatin doses, ratios

UR - http://www.scopus.com/inward/record.url?scp=0027741409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027741409&partnerID=8YFLogxK

M3 - Article

VL - 4

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 4

ER -